Understand the source comparison
Best Peptides for Osteoarthritis: Research Application Comparison
Before selecting peptides for joint research, understanding their distinct mechanisms and research contexts is essential. BPC-157 VEGF pathway modulation, angiogenesis in peri-articular tissue Tendon-bone healing, ligament repair, cartilage nutrient diffusion
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting peptides for joint research, understanding their distinct mechanisms and research contexts is essential.
- BPC-157
- VEGF pathway modulation, angiogenesis in peri-articular tissue
- Tendon-bone healing, ligament repair, cartilage nutrient diffusion
- 200–400 mcg/kg daily (rodent models)
- 4–8 weeks for tissue remodeling markers
- Best evidence for soft tissue and vascular components of joint pathology. Cartilage effects are secondary to improved nutrient delivery
- TB-500
- Actin upregulation, cell migration, anti-inflammatory cytokine modulation
- Synovial inflammation reduction, chondrocyte migration into damaged zones
- 2–6 mg total dose weekly (rodent models)
- 6–12 weeks for histological changes
- Strong evidence for reducing acute inflammatory markers. Less clear whether it alters long-term degenerative progression
- GHK-Cu
- Collagen synthesis via lysyl oxidase cofactor activity, MMP suppression
- Type II collagen deposition, extracellular matrix stabilization
- 1–3 mg/kg every other day (rodent models)
- 8–16 weeks for biomechanical property changes
- Most direct evidence for cartilage matrix effects. Requires sustained administration and works best in early-stage degeneration models
- KPV
- NF-κB pathway suppression, melanocortin receptor activation
- Synovial macrophage activity reduction, pro-inflammatory cytokine suppression
- 500 mcg–1 mg daily (rodent models)
- 2–4 weeks for cytokine level changes
- Potent short-term anti-inflammatory. Unclear whether inflammation suppression alone translates to structural joint preservation
- Thymalin
- Immune regulation, T-cell modulation
- Age-related immune dysregulation, inflammaging in elderly cohorts
- 5–10 mg intramuscular 2–3× weekly (human observational data)
- 8–12 weeks for immune marker changes
- Limited Western research replication. Most data from Russian gerontology studies with modest effect sizes